Cargando…
CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance
Background: Diagnostic delay and neurologic deterioration are still a problem for the treatment of rapidly progressing CNS lymphoma (CNSL); there is an unmet need for a diagnostic test with a high diagnostic yield and limited risk, minimizing the time to the initiation of effective treatment. Method...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032970/ https://www.ncbi.nlm.nih.gov/pubmed/33841320 http://dx.doi.org/10.3389/fneur.2021.654543 |
_version_ | 1783676321977597952 |
---|---|
author | Masouris, Ilias Manz, Kirsi Pfirrmann, Markus Dreyling, Martin Angele, Barbara Straube, Andreas Langer, Sigrid Huber, Marion Koedel, Uwe Von Baumgarten, Louisa |
author_facet | Masouris, Ilias Manz, Kirsi Pfirrmann, Markus Dreyling, Martin Angele, Barbara Straube, Andreas Langer, Sigrid Huber, Marion Koedel, Uwe Von Baumgarten, Louisa |
author_sort | Masouris, Ilias |
collection | PubMed |
description | Background: Diagnostic delay and neurologic deterioration are still a problem for the treatment of rapidly progressing CNS lymphoma (CNSL); there is an unmet need for a diagnostic test with a high diagnostic yield and limited risk, minimizing the time to the initiation of effective treatment. Methods: In this prospective monocentric study, we analyzed the utility of CXCL13 and CXCL9 as diagnostic, therapeutic and prognostic biomarkers for CNSL. Cerebrospinal fluid (CSF) from 155 consecutive patients admitted with brain lesions of various origins was collected. Levels of CXCL13 and CXCL9 were analyzed by ELISA. Additionally, CSF was analyzed during CNSL disease course (relapse, remission, progress) in 17 patients. Results: CXCL13 and CXCL9 CSF levels were significantly increased in patients with CNSL compared to control patients with lesions of other origin. Using logistic regression and a minimal-p-value approach, a cut-off value of 80 pg/ml for CXCL13 shows high sensitivity (90.7%) and specificity (90.1%) for the diagnosis of active CNSL. CXCL9 at a cut-off value of 84 pg/ml is less sensitive (61.5%) and specific (87.1%). Both cytokines correlate with the clinical course and response to therapy. Conclusions: Our results confirm the excellent diagnostic potential of CXCL13 and introduce CXCL9 as a novel albeit less powerful marker for PCNSL. |
format | Online Article Text |
id | pubmed-8032970 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80329702021-04-10 CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance Masouris, Ilias Manz, Kirsi Pfirrmann, Markus Dreyling, Martin Angele, Barbara Straube, Andreas Langer, Sigrid Huber, Marion Koedel, Uwe Von Baumgarten, Louisa Front Neurol Neurology Background: Diagnostic delay and neurologic deterioration are still a problem for the treatment of rapidly progressing CNS lymphoma (CNSL); there is an unmet need for a diagnostic test with a high diagnostic yield and limited risk, minimizing the time to the initiation of effective treatment. Methods: In this prospective monocentric study, we analyzed the utility of CXCL13 and CXCL9 as diagnostic, therapeutic and prognostic biomarkers for CNSL. Cerebrospinal fluid (CSF) from 155 consecutive patients admitted with brain lesions of various origins was collected. Levels of CXCL13 and CXCL9 were analyzed by ELISA. Additionally, CSF was analyzed during CNSL disease course (relapse, remission, progress) in 17 patients. Results: CXCL13 and CXCL9 CSF levels were significantly increased in patients with CNSL compared to control patients with lesions of other origin. Using logistic regression and a minimal-p-value approach, a cut-off value of 80 pg/ml for CXCL13 shows high sensitivity (90.7%) and specificity (90.1%) for the diagnosis of active CNSL. CXCL9 at a cut-off value of 84 pg/ml is less sensitive (61.5%) and specific (87.1%). Both cytokines correlate with the clinical course and response to therapy. Conclusions: Our results confirm the excellent diagnostic potential of CXCL13 and introduce CXCL9 as a novel albeit less powerful marker for PCNSL. Frontiers Media S.A. 2021-03-26 /pmc/articles/PMC8032970/ /pubmed/33841320 http://dx.doi.org/10.3389/fneur.2021.654543 Text en Copyright © 2021 Masouris, Manz, Pfirrmann, Dreyling, Angele, Straube, Langer, Huber, Koedel and Von Baumgarten. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Masouris, Ilias Manz, Kirsi Pfirrmann, Markus Dreyling, Martin Angele, Barbara Straube, Andreas Langer, Sigrid Huber, Marion Koedel, Uwe Von Baumgarten, Louisa CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance |
title | CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance |
title_full | CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance |
title_fullStr | CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance |
title_full_unstemmed | CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance |
title_short | CXCL13 and CXCL9 CSF Levels in Central Nervous System Lymphoma—Diagnostic, Therapeutic, and Prognostic Relevance |
title_sort | cxcl13 and cxcl9 csf levels in central nervous system lymphoma—diagnostic, therapeutic, and prognostic relevance |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8032970/ https://www.ncbi.nlm.nih.gov/pubmed/33841320 http://dx.doi.org/10.3389/fneur.2021.654543 |
work_keys_str_mv | AT masourisilias cxcl13andcxcl9csflevelsincentralnervoussystemlymphomadiagnostictherapeuticandprognosticrelevance AT manzkirsi cxcl13andcxcl9csflevelsincentralnervoussystemlymphomadiagnostictherapeuticandprognosticrelevance AT pfirrmannmarkus cxcl13andcxcl9csflevelsincentralnervoussystemlymphomadiagnostictherapeuticandprognosticrelevance AT dreylingmartin cxcl13andcxcl9csflevelsincentralnervoussystemlymphomadiagnostictherapeuticandprognosticrelevance AT angelebarbara cxcl13andcxcl9csflevelsincentralnervoussystemlymphomadiagnostictherapeuticandprognosticrelevance AT straubeandreas cxcl13andcxcl9csflevelsincentralnervoussystemlymphomadiagnostictherapeuticandprognosticrelevance AT langersigrid cxcl13andcxcl9csflevelsincentralnervoussystemlymphomadiagnostictherapeuticandprognosticrelevance AT hubermarion cxcl13andcxcl9csflevelsincentralnervoussystemlymphomadiagnostictherapeuticandprognosticrelevance AT koedeluwe cxcl13andcxcl9csflevelsincentralnervoussystemlymphomadiagnostictherapeuticandprognosticrelevance AT vonbaumgartenlouisa cxcl13andcxcl9csflevelsincentralnervoussystemlymphomadiagnostictherapeuticandprognosticrelevance |